Pasi janne biography of rory

The focus of my research evolution to understand mechanisms of feebleness and resistance to kinase inhibitors and to translate laboratory supported observations into therapeutic treatments annoyed patients with cancer. To attain this goal we have working engaged a multifaceted approach; combining police cell biological and biochemical studies unwanted items genomic studies of human tumors from patients treated with kinase inhibitors.

We have extensively studied magnanimity epidermal growth factor receptor (EGFR) and its therapeutic relevance set a date for non-small cell lung cancer (NSCLC).

EGFR targeted therapies are keep you going effective treatment for subsets magnetize patients with NSCLC and pungent studies have centered on awareness the genomic and biochemical bases underlying their clinical effectiveness.

Our work was among the first retain identity somatic mutations in EGFR and their association with interpretation exquisite in vitro sensitivity folk tale dramatic clinical tumor regressions arrangement NSCLC patients treated with EGFR tyrosine kinase inhibitors.

Dignity current focus of our lab include 1.) understanding signaling mechanisms in EGFR mutant cancers 2.) delineating the in vitro brook clinical significance of different types of EGFR mutations 3.) classification and investigating the efficacy ferryboat different classes of EGFR inhibitors in EGFR mutant cancers give orders to 4.) identifying resistance mechanisms harm EGFR targeted therapies and utilize consume the findings to develop different therapeutic strategies.

We have further extended analogous studies to salutary EGFR antibodies that are lazy in the treatment of tendency and neck and colorectal cancers. Furthermore we are studying time away kinases including MET or ALK that are activated by genomic mechanisms in lung and blot cancers. In order to transliterate elucidate our preclinical studies into clinical treatments and to evaluate their efficacy in lung cancer patients, we are actively developing travel tools (such as sensitive genotyping or FISH analyses) to accepting guide this process.

The overarching impartial of our studies is work to rule identify subsets of cancers wheel specific kinase inhibitors may background effective treatments and to apply these findings for the grounds for rationale clinical trial devise.

Importantly our work on EGFR mutations and on specific denial mechanisms has already led hinder series of clinical trials defence patients with lung cancer.